Search Results
Oct 22, 2025, 07:00 ET Argentina Lithium & Energy Corp. Announces Initial Mineral Resource Estimate at the Rincon West Lithium Project
volume with an average grade of 296 mg/lithium, representing 238,000 tonnes Lithium Carbonate Equivalent (LCE), and Inferred Resource of 0.08 km3 brine volume with an average grade of 216 mg/l lithium, representing 64,000
More news about: Argentina Lithium & Energy Corp.
Oct 22, 2025, 02:00 ET ACM Biolabs報告：晚期實體瘤患者肌肉注射ACM-CpG顯現良好安全性信號及早期藥效學活性
臨床前實驗表明，ACM納米顆粒制劑可從根本上改變CpG的作用機制，通過全面激活免疫「冷」腫瘤中的TLR9受體，實現髓系細胞調控。目前一期試驗（NCT06587295）[i]正在新加坡國立癌症中心招募晚期實體瘤患者，旨在評估ACM-CpG的安全性、耐受性及藥效學。 早期臨床數據顯示，這些臨床前發現結果正在人體中得到驗證。在晚期實體瘤患者中，每周或每兩周肌肉注射低至0.25mg CpG的ACM-CpG，通過免疫生物標志物數據證實，可引發強勁的全身免疫激活。該療法展現出高度良好的安全性與耐受性，截至目前未觀察到劑量限制性毒性。 ACM Biolabs首席執行官Madhavan
More news about: ACM Biolabs
Oct 22, 2025, 02:00 ET ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors
translating into humans. In patients with advanced solid tumors, intramuscular administration of ACM-CpG - at weekly or biweekly doses as low as 0.25mg CpG – has demonstrated robust systemic immune activation as evidenced through immune biomarker data. The therapy shows a highly favorable safety and
More news about: ACM Biolabs
Oct 22, 2025, 02:00 ET ACM Biolabs Reports Favorable Safety Signals and Early Pharmacodynamics from Intramuscular Administration of ACM-CpG in Patients with Advanced Solid Tumors
translating into humans. In patients with advanced solid tumors, intramuscular administration of ACM-CpG - at weekly or biweekly doses as low as 0.25mg CpG – has demonstrated robust systemic immune activation as evidenced through immune biomarker data. The therapy shows a highly favorable safety and
More news about: ACM Biolabs
Oct 22, 2025, 02:00 ET ACM Biolabs berichtet über günstige Sicherheitssignale sowie frühe Pharmakodynamik der intramuskulären Verabreichung von ACM-CpG bei Patienten mit fortgeschrittenen soliden Tumoren
Patienten mit fortgeschrittenen soliden Tumoren hat die intramuskuläre Verabreichung von ACM-CpG – in wöchentlichen oder zweiwöchentlichen Dosen von nur 0,25 mg CpG – eine robuste systemische Immunaktivierung gezeigt, die durch Immun-Biomarker-Daten belegt ist. Die Therapie weist ein sehr günstiges Sicherheits-
More news about: ACM Biolabs
Oct 22, 2025, 02:00 ET ACM Biolabs informa de seguridad en la administración intramuscular de ACM-CpG
a humanos. En pacientes con tumores sólidos avanzados, la administración intramuscular de ACM-CpG (en dosis semanales o quincenales de tan solo 0,25 mg de CpG) ha demostrado una sólida activación inmunitaria sistémica, como lo demuestran los datos de biomarcadores inmunitarios. La terapia muestra un
More news about: ACM Biolabs
Oct 22, 2025, 02:00 ET ACM Biolabs relata sinais favoráveis de segurança e farmacodinâmica inicial da administração intramuscular de ACM-CpG em pacientes com tumor sólido avançado
humanos. Em pacientes com tumores sólidos avançados, a administração intramuscular de ACM-CpG - em doses semanais ou quinzenais tão baixas quanto 0,25 mg de CpG – demonstrou uma ativação imunológica sistêmica robusta, conforme evidenciado pelos dados de biomarcadores imunológicos. A terapia apresenta um
More news about: ACM Biolabs
Oct 22, 2025, 02:00 ET ACM Biolabs rapporte des signaux d'innocuité favorables et une pharmacodynamique précoce pour l'administration intramusculaire d'ACM-CpG chez des patients atteints de tumeurs solides avancées
patients atteints de tumeurs solides avancées, l'administration intramusculaire d'ACM-CpG - à des doses hebdomadaires ou bihebdomadaires de seulement 0,25 mg CpG - a démontré une activation immunitaire systémique robuste, comme en témoignent les données sur les biomarqueurs immunitaires. Le traitement présente
More news about: ACM Biolabs
Oct 22, 2025, 02:00 ET ACM Biolabs informa señales de seguridad favorables y farmacodinámica inicial tras la administración intramuscular de ACM-CpG en pacientes con tumores sólidos avanzados
humanos. En pacientes con tumores sólidos avanzados, la administración intramuscular de ACM-CpG, en dosis semanales o quincenales tan bajas como 0,25 mg de CpG, ha demostrado una sólida activación inmunitaria sistémica, como lo demuestran los datos de biomarcadores inmunitarios. La terapia muestra un
More news about: ACM Biolabs
Oct 22, 2025, 02:00 ET ACM 바이오랩스, 진행성 고형암 환자 대상 ACM-CpG 근육 내 투여에서 양호한 안전성 실마리정보 및 초기 약력학 결과 보고
중대한 미충족 의료 수요를 해결할 수 있을 것"이라고 덧붙였다. 싱가포르 국립암센터 종양내과 수석 컨설턴트인 아미트 자인(Amit Jain) 박사는 "현재까지 관찰된 안전성 프로필과 명확한 약력학적 활성은 매우 고무적"이라며 "0.25mg 용량군에 등록된 환자 3명 중 2명이 단독요법만으로 8개월간 지속적인 질병 통제를 유지하고 있다"라고 말했다. 그는 "진행성 암 환자를 위해 전달 방식을 최적화하고 치료 잠재력을 극대화할 수 있는 방안을 모색할 수 있기를 기대한다"고 덧붙였다.
More news about: ACM Biolabs
Oct 21, 2025, 19:30 ET PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
evaluation. Closely monitor blood glucose levels in patients with, or at risk for, diabetes mellitus or hyperglycemia. If blood glucose is elevated (>250 mg/dL), withhold PADCEV. Pneumonitis/Interstitial Lung Disease (ILD) Severe, life-threatening or fatal pneumonitis/ILD
More news about: Astellas Pharma Inc.
Oct 21, 2025, 17:00 ET Dreamegg Unveils Sunrise 1+: The Next Generation Sunrise Alarm Clock for Stress-Free Sleep and Wake Routines
https://www.amazon.com/dp/B0D5MG7K8R?maas=maas_adg_C291AC481A849CBA1AFC2F552B945750_afap_abs&ref_=aa_maas&tag=maas Amazon UK:
More news about: Dreamegg
Oct 21, 2025, 08:35 ET Hanyang University Researchers Develop Novel Facet-Guided Metal Plating Strategy, Improving Stability of Anode-Free Metal Batteries
batteries, instead of starting with an Mg anode, only a bare metal, usually copper (Cu) or Zinc (Zn), current collector is used as the anode side. When the batteries are first charged, Mg from the cathode deposits directly onto this collector, forming a thin Mg layer that acts as the anode. This avoids excess
More news about: Hanyang University
Oct 21, 2025, 08:00 ET Crystalys Therapeutics Advances Phase 3 Trials of Dotinurad for the Treatment of Gout with Dosing of First Patients
tophaceous gout in people with chronic or undertreated disease. Despite available therapies that aim to reduce uric acid levels below the target 6 mg/dL, a major treatment gap remains between first-line xanthine oxidase inhibitors (XOIs) and last-line uricase therapy. Currently, no suitable second-line
More news about: Crystalys Therapeutics
Oct 21, 2025, 07:05 ET Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
diabetes who have obesity or are overweight. Patients in both trials are being randomized to one of four weekly treatment arms: VK2735 7.5 mg; VK2735 12.5 mg; VK2735 17.5 mg; and placebo. About GLP-1 and Dual GLP-1/GIP Agonists
More news about: Viking Therapeutics, Inc.
Oct 21, 2025, 06:59 ET Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
bempikibart for 36 weeks, with follow-up out to 52 weeks. Dosing includes an initial loading regimen of 200mg of bempikibart dosed weekly for four doses, followed by a maintenance dose of 200mg every-other-week over a 32-week period for a total dosing period of 36 weeks. Efficacy will be evaluated on
More news about: Q32 Bio
Oct 20, 2025, 16:35 ET NYS Legislation Introduced to Prevent Legionnaires' Disease in Wake of Recent Outbreaks and Cases
Water Treatment and Management: Public water system operators are required to maintain specific levels of disinfectant residuals (at least 0.5 mg/L of free chlorine) and regular monitoring of water quality. Public Notification: Water system
More news about: Prevent Legionnaires'
Oct 20, 2025, 12:48 ET Long-Term Study of Extended-Release Guaifenesin Shows Symptom Relief in Stable Chronic Bronchitis Patients
Assessment of Satisfaction for Patients (GASP) Study, the first long-term evaluation of extended-release (ER) guaifenesin (Mucinex) at 1200 mg twice daily (2,400 mg) over 12 weeks in patients with stable chronic bronchitis (SCB). The findings demonstrate clinically meaningful reductions in cough and sputum
More news about: MUCINEX
Oct 20, 2025, 10:34 ET MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025
mass and demonstrating improved lipid-lowering effects compared to survodutide. In the Phase 1 multiple ascending dose (MAD) trial in obesity, the 32 mg dose of DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction.
More news about: MetaVia Inc.
Oct 20, 2025, 08:33 ET Surf Bio to Present SnapShot™ Platform at PODD 2025, Showcasing Potential to Transform Subcutaneous Delivery of High-Dose Biologic Therapies
devices. Powered by Surf Bio's proprietary, patent-protected surfactant polymer, the platform enables protein concentrations of up to 600 mg/mL and dose delivery up to 1,000 mg, addressing one of the most persistent challenges in biologic formulation and delivery. "Monoclonal antibodies
More news about: Surf Bio, Inc.
Oct 20, 2025, 08:00 ET RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets. RINVOQ LQ is taken twice a day with or without food. RINVOQ LQ is available in a 1 mg/mL oral solution. RINVOQ LQ is not the same as RINVOQ tablets. Do not switch between
More news about: AbbVie
Oct 20, 2025, 07:00 ET Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
Effect of CagriSema 2.4mg/2.4mg on Body Composition, Muscle Strength & Physical Function: REDEFINE 1. Oral presentation – Wednesday 5 November; 3:45-4:00 PM ET STEP UP (Semaglutide 7.2 mg)
More news about: NOVO NORDISK INC.
Oct 20, 2025, 07:00 ET Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
Effect of CagriSema 2.4mg/2.4mg on Body Composition, Muscle Strength & Physical Function: REDEFINE 1. Oral presentation – Wednesday 5 November; 3:45-4:00 PM ET STEP UP (Semaglutide 7.2 mg)
More news about: NOVO NORDISK INC.
Oct 20, 2025, 07:00 ET HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025
Enhanced safety: Demonstrates a cytopenia-sparing profile, with no dose-limiting toxicities observed up to 24 mg/kg and receptor occupancy >90% at ≥1.28 mg/kg, supporting a broad therapeutic window. Robust immune activation: Engineered
More news about: HanchorBio Inc.
Oct 20, 2025, 04:30 ET Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
with advanced solid tumors regardless of CLDN18.2 expression receive ATG-022 (0.3-3.0 mg/kg Q3W) to evaluate safety, tolerability, and pharmacokinetics; CLDN18.2-positive (≥IHC 1+, 1%) patients are treated at 1.8 or 2.4 mg/kg in dose expansion to evaluate the efficacy and safety.
More news about: Antengene Corporation Limited